经过20年的真实世界与纳塔利祖马布的经验,我们学到了一些教训
Bhupendra O Khatri1, Tayo Olapo1, Sara Beals1
1The Regional MS Center, Center for Neurological Disorders SC, Ascension St. Francis Hospital, 3237 S. 16th Street, Milwaukee, WI 53215, United States.
Multiple sclerosis and related disorders
|October 22, 2023
概括
纳塔利祖马布 (NTZ) 对于多发性硬化症 (MS) 是有效的,但具有逐渐多焦点白内障 (PML) 的风险. 这项研究在大量队列中没有发现PML病例,这表明仔细监测和延长剂量间隔可能会降低风险.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 纳塔利祖马布 (NTZ) 是治疗多发性硬化症 (MS) 的关键疗法.
- 治疗NTZ与渐进式多焦点白血脑病 (PML) 的风险增加有关.
- 在一个单一中心使用NTZ的20年经验表明没有PML病例.
结论:
- 仔细的临床监测和EID的使用可以减轻在NTZ的MS患者中PML的风险.
- 这些策略可能允许持续NTZ有效性,同时提高患者的安全性.
更多相关视频
相关概念视频
Immunological Memory
634
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
634
Desensitization and Tachyphylaxis
1.8K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.8K
Nephrotic Syndrome III : Nursing Management
17
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
17
Nephrotic Syndrome II : Assessment and Medical Management
8
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
8
Active versus Passive Immunity
663
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
Active Immunity
Active immunity refers to the resistance one develops...
663
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148


